Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion ; volume:34 ; number:1 ; day:6 ; month:11 ; year:2023 ; pages:724-725 ; date:1.2024
European radiology ; 34, Heft 1 (6.11.2023), 724-725, 1.2024
- Urheber
-
Taouli, Bachir
Ba-Ssalamah, Ahmed
Chapiro, Julius
Chhatwal, Jagpreet
Fowler, Kathryn
Kang, Tae Wook
Knobloch, Gesine
Koh, Dow-Mu
Kudo, Masatoshi
Lee, Jeong Min
Murakami, Takamichi
Pinato, David J.
Ringe, Kristina I.
Song, Bin
Tabrizian, Parissa
Wang, Jin
Yoon, Jeong Hee
Zeng, Mengsu
Zhou, Jian
Vilgrain, Valérie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00330-023-10342-7
- URN
-
urn:nbn:de:101:1-2024032722154374632975
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Taouli, Bachir
- Ba-Ssalamah, Ahmed
- Chapiro, Julius
- Chhatwal, Jagpreet
- Fowler, Kathryn
- Kang, Tae Wook
- Knobloch, Gesine
- Koh, Dow-Mu
- Kudo, Masatoshi
- Lee, Jeong Min
- Murakami, Takamichi
- Pinato, David J.
- Ringe, Kristina I.
- Song, Bin
- Tabrizian, Parissa
- Wang, Jin
- Yoon, Jeong Hee
- Zeng, Mengsu
- Zhou, Jian
- Vilgrain, Valérie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Hepatocellular carcinoma 2009 and beyond : 25 tables